"Unicorn" start-up Owkin and AstraZeneca are developing an AI-powered breast cancer prescreening solution under a partnership announced on 2 October.
According to French-American Owkin, which bills itself as “the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics,” the AI tool in development will assess cell morphology in digitized
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?